Orion BioScience Inc — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Orion BioScience Inc. has developed a Soluble Antige
Orion BioScience Inc — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $220,834
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- KS
- Period
- —
Description
DESCRIPTION (provided by applicant): Orion BioScience Inc. has developed a Soluble Antigen Array (SAgA) therapeutic that displays multiple copies of aquaporin-4 epitope for targeted clearance of the auto reactive NMO-IgG antibody in patients with neuromyelitis optica (NMO). The product is intended to selectively clear NMO-IgG while limiting interaction with other non-NMO specific antibodies, thereby reducing side effects often seen with global immunosuppressants. Orion's SAgA technology displays multiplecopies of AQP4 epitope along a flexible polymer backbone and will initiate endogenous reticuloendothelial clearance mechanisms through antibody agglomeration. Blindness is the primary clinical outcome of NMO induced attacks; however, severe attacks can also lead to extensive transverse myelitis and paralysis. The ten year mortality rate after initial diagnosis in patients with NMO is gt25%, however, no dedicated NMO therapeutic is available. A majority of symptoms result from the binding of NMO-IgG to AQP4,